Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Listening for Needs. Delivering Solutions. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Investor Overview

News Releases

10 Nov '23
Company Expects to Complete Irish Examinership and Emerge from Chapter 11 in Coming Days DUBLIN – November 10, 2023 – Mallinckrodt plc (OTCMKTS: MNKTQ) (in examination under Part 10 of the Companies Act 2014 of Ireland, and hereinafter “Mallinckrodt” or the “Company”), a global specialty
08 Nov '23
– A total of 11 scientific abstracts from Mallinckrodt's research for adults with HRS with rapid reduction in kidney function 1  provide further insight into the clinical efficacy, safety, and real-world utility of TERLIVAZ treatment for appropriate patients – – Mallinckrodt's presence to include
01 Nov '23
–Three scientific abstracts via one oral and two poster presentations detail the Company's latest clinical research findings on the therapeutic effect of TERLIVAZ for adults with HRS involving rapid reduction in kidney function 1 – DUBLIN , Nov. 1, 2023 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS:
go back to the top of the page